Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies

J Cancer Res Clin Oncol. 2000 Oct;126(10):549-59. doi: 10.1007/pl00008465.


Over the past decades, Positron Emission Tomography has opened a new field of imaging. Nowadays, this technique is being used for diagnosing, staging disease as well as for prognostic stratification and monitoring therapy. In this respect, [18F]fluorodeoxyglucose (FdGlc) is by far the most commonly used PET agent. Many factors have been identified being responsible for a high uptake of this agent in malignancy. However, additional factors such as tumour treatment may interfere with the uptake mechanism. Knowledge of all these factors is a prerequisite for an optimal interpretation of PET studies and, consequently, for a reliable judgement of tumour status. In this article, a review is given of the factors influencing FdGlc uptake and the implications for clinical studies.

Publication types

  • Review

MeSH terms

  • Citric Acid Cycle
  • Fluorodeoxyglucose F18 / metabolism*
  • Gene Expression Regulation, Enzymologic
  • Gene Expression Regulation, Neoplastic
  • Glycolysis
  • Hexokinase / metabolism
  • Humans
  • Mitochondria / metabolism
  • Monosaccharide Transport Proteins / metabolism
  • Neoplasms / metabolism
  • Radiopharmaceuticals / metabolism*
  • Tomography, Emission-Computed* / methods
  • Up-Regulation


  • Monosaccharide Transport Proteins
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Hexokinase